JP2016513717A5 - - Google Patents

Download PDF

Info

Publication number
JP2016513717A5
JP2016513717A5 JP2016502662A JP2016502662A JP2016513717A5 JP 2016513717 A5 JP2016513717 A5 JP 2016513717A5 JP 2016502662 A JP2016502662 A JP 2016502662A JP 2016502662 A JP2016502662 A JP 2016502662A JP 2016513717 A5 JP2016513717 A5 JP 2016513717A5
Authority
JP
Japan
Prior art keywords
group
formula
disorder
trpc5
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016502662A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016513717A (ja
JP6360149B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/027920 external-priority patent/WO2014143799A2/en
Publication of JP2016513717A publication Critical patent/JP2016513717A/ja
Publication of JP2016513717A5 publication Critical patent/JP2016513717A5/ja
Application granted granted Critical
Publication of JP6360149B2 publication Critical patent/JP6360149B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016502662A 2013-03-15 2014-03-14 置換キサンチンおよびその使用方法 Active JP6360149B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361789724P 2013-03-15 2013-03-15
US61/789,724 2013-03-15
PCT/US2014/027920 WO2014143799A2 (en) 2013-03-15 2014-03-14 Substituted xanthines and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2016513717A JP2016513717A (ja) 2016-05-16
JP2016513717A5 true JP2016513717A5 (enExample) 2017-04-20
JP6360149B2 JP6360149B2 (ja) 2018-07-18

Family

ID=50680155

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016502662A Active JP6360149B2 (ja) 2013-03-15 2014-03-14 置換キサンチンおよびその使用方法

Country Status (31)

Country Link
US (7) US9359359B2 (enExample)
EP (1) EP2970303B3 (enExample)
JP (1) JP6360149B2 (enExample)
KR (1) KR102227629B1 (enExample)
CN (2) CN105143229B (enExample)
AU (1) AU2014228206C1 (enExample)
CA (1) CA2899646C (enExample)
CL (1) CL2015002738A1 (enExample)
CY (1) CY1119042T1 (enExample)
DK (1) DK2970303T6 (enExample)
EA (1) EA028815B1 (enExample)
ES (1) ES2636835T7 (enExample)
HR (1) HRP20170840T4 (enExample)
HU (1) HUE033528T4 (enExample)
IL (1) IL240216B (enExample)
LT (1) LT2970303T (enExample)
MX (1) MX370372B (enExample)
MY (1) MY189912A (enExample)
NZ (1) NZ711718A (enExample)
PE (1) PE20151779A1 (enExample)
PH (1) PH12015502141B1 (enExample)
PL (1) PL2970303T6 (enExample)
PT (1) PT2970303T (enExample)
RS (1) RS56066B2 (enExample)
SG (1) SG11201506479TA (enExample)
SI (1) SI2970303T1 (enExample)
TW (1) TWI609867B (enExample)
UA (1) UA117470C2 (enExample)
UY (1) UY35488A (enExample)
WO (1) WO2014143799A2 (enExample)
ZA (1) ZA201505414B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173750B2 (en) 2009-04-23 2012-05-08 ATRP Solutions, Inc. Star macromolecules for personal and home care
PT2970303T (pt) 2013-03-15 2017-06-23 Hydra Biosciences Inc Xantinas substituídas e métodos de sua utilização
WO2016023831A1 (en) * 2014-08-11 2016-02-18 Hydra Biosciences, Inc. Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives
WO2016159747A1 (en) 2015-03-27 2016-10-06 Latvian Institute Of Organic Synthesis Ethynylxanthines, preparation and use as calcium ion channel modulators
GB2553684B (en) 2015-03-27 2020-06-03 Latvian Inst Organic Synthesis Ethynylxanthines, preparation and use for cancer treatment
WO2016159746A1 (en) 2015-03-27 2016-10-06 Latvian Institute Of Organic Synthesis Novel ethynylxanthines, their preparation and use as inhibitors of matrix metalloproteinases and angiogenesis
EP3280417B1 (en) * 2015-04-08 2020-07-29 Lewis and Clark Pharmaceuticals, Inc. Xanthine-substituted alkynyl carbamates/reverse carbamates as a2b antagonists
CN107118586A (zh) * 2016-02-24 2017-09-01 中国科学技术大学 含氮杂环基取代的烯类化合物的用途
GB201702160D0 (en) 2017-02-09 2017-03-29 Univ Leeds Innovations Ltd Inhibitors for use in therapy
WO2018157800A1 (en) * 2017-02-28 2018-09-07 National Institute Of Biological Sciences, Beijing Mlkl inhibitors
US11666577B2 (en) * 2017-02-28 2023-06-06 National Institute Of Biological Sciences, Beijing MLKL inhibitors
AU2018299824B2 (en) 2017-07-11 2022-06-16 Boehringer Ingelheim International Gmbh Novel substituted xanthine derivatives
US11623930B2 (en) 2018-03-05 2023-04-11 Goldfinch Bio, Inc. Imidazodiazepinediones and methods of use thereof
CN113166150B (zh) * 2018-12-12 2023-12-01 勃林格殷格翰国际有限公司 经取代的黄嘌呤衍生物
EA202191588A1 (ru) * 2018-12-12 2021-10-18 Бёрингер Ингельхайм Интернациональ Гмбх Замещенные ксантиновые производные
CN112979651B (zh) * 2021-04-09 2022-02-01 南京纽邦生物科技有限公司 一种副黄嘌呤的制备方法
CN113354646B (zh) * 2021-07-06 2022-11-15 南开大学 8-芳氧基烷氧基取代黄嘌呤衍生物及其制备方法和应用
CN115636831B (zh) * 2022-10-27 2024-11-08 中国药科大学 稠合嘧啶二酮类化合物、其用途以及药物组合物
TW202440582A (zh) 2022-12-20 2024-10-16 德商百靈佳殷格翰國際股份有限公司 7-(4-氯苯甲基)-1-(3-羥丙基)-3-甲基-8-(3-(三氟甲氧基)-苯氧基)-3,7-二氫-1h -嘌呤-2,6-二酮之製備方法
CN118373832B (zh) * 2023-01-20 2025-01-28 深圳晶蛋生物医药科技有限公司 大环类化合物、其药物组合物及其应用
TW202448476A (zh) 2023-02-06 2024-12-16 德商百靈佳殷格翰國際股份有限公司 包含7-(4-氯苄基)-1-(3-羥丙基)-3-甲基-8-(3-(三氟甲氧基)-苯氧基)-3,7-二氫-1h -嘌呤-2,6-二酮之醫藥組合物
KR20250141831A (ko) * 2023-02-08 2025-09-29 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 잔틴계 화합물 및 이의 용도
WO2025250920A1 (en) 2024-05-31 2025-12-04 Gfb (Abc), Llc Pyridazinone phosphate compounds, pharmaceutical compositions, and medical uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4304650A1 (de) * 1993-02-16 1994-08-18 Thomae Gmbh Dr K Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US6878715B1 (en) * 1994-02-18 2005-04-12 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
JP4191269B2 (ja) 1996-05-17 2008-12-03 興和株式会社 新規なアニリド化合物及びこれを含有する医薬
JPH10318487A (ja) 1997-05-16 1998-12-04 Mitsubishi Gas Chem Co Inc 真空断熱材用ゲッタ
US6075029A (en) * 1998-01-02 2000-06-13 Cell Therapeutics, Inc. Xanthine modulators of metabolism of cellular P-450
US6187780B1 (en) * 1998-04-16 2001-02-13 Boehringer Ingelheim Pharma Kg Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity
MXPA01010143A (es) * 1999-04-09 2003-07-14 Cell Therapeutics Inc Derivados de xantina y analogos como inhibidores de transmision de senales celulares.
RU2003103103A (ru) * 2000-07-04 2004-08-20 Ново Нордиск А/С (DK) Гетероциклические соединения, которые являются ингибиторами фермента dpp-iv
WO2002046172A2 (en) 2000-12-07 2002-06-13 Cv Therapeutics, Inc. Substituted 1, 3, 5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis
EA007485B1 (ru) * 2001-02-24 2006-10-27 Берингер Ингельхайм Фарма Гмбх Унд Ко. Кг Производные ксантина, способ их получения, фармацевтическая композиция на их основе и способ ее получения
ATE520694T1 (de) * 2001-11-09 2011-09-15 Gilead Palo Alto Inc A2b-adenosinrezeptorantagonisten
AU2003249604B2 (en) * 2003-05-06 2011-06-30 Gilead Sciences, Inc. A2B adenosine receptor antagonists
US20050182011A1 (en) 2003-11-13 2005-08-18 Eric Olson Inhibition of TRP channels as a treatment for cardiac hypertrophy and heart failure
US7393827B2 (en) 2004-12-30 2008-07-01 Diakine Therapeutics, Inc. Pharmaceutical compositions and methods for restoring β-cell mass and function
WO2006089168A2 (en) 2005-02-18 2006-08-24 Cornell Research Foundation, Inc. Methods for modulating ion channels
JP2009504592A (ja) * 2005-08-10 2009-02-05 スミスクライン・ビーチャム・コーポレイション 選択的hm74aアゴニストとしてのキサンチン誘導体
ATE459620T1 (de) 2005-09-06 2010-03-15 Glaxosmithkline Llc Benzimidazolthiophenverbindungen als plk- modulatoren
JP2009518333A (ja) * 2005-12-07 2009-05-07 ユセベ ファルマ ソシエテ アノニム キサンチン誘導体、その調製方法及びその使用
TW201900217A (zh) * 2005-12-22 2019-01-01 美商海卓勒生物科學公司 用於調節trpa1功能之化合物
CA2637674A1 (en) 2006-01-19 2007-07-26 Abbott Laboratories 2-imino-benzimidazoles
WO2007101213A2 (en) 2006-02-28 2007-09-07 Kalypsys, Inc. Novel 2-oxo-1,2,3,4-tetrahydropyrimidines, bicyclic pyrimidine diones and imidazolidine-2,4-diones useful as inducible nitric oxide synthase inhibitors
US20090269313A1 (en) * 2006-07-19 2009-10-29 Diakine Therapeutics, Inc. Encapsulation system
WO2009157938A1 (en) * 2008-06-26 2009-12-30 Cv Therapeutics, Inc. A2b adenosine receptor antagonists for treating cancer
US20120148604A1 (en) 2009-08-20 2012-06-14 Transposagen Biopharmaceuticals, Inc. Trp inhibitors and uses thereof
WO2011114184A1 (en) * 2010-03-15 2011-09-22 Glenmark Pharmaceuticals S.A. Amides of heterocyclic compounds as trpa1 inhibitors
US9260430B2 (en) 2010-06-08 2016-02-16 Hydra Biosciences, Inc. Use of TRPA1 antagonists to prevent or treat infections caused by biological-warfare agents
JP2013023102A (ja) * 2011-07-22 2013-02-04 Panasonic Corp 列車情報提供システム
JP2014521724A (ja) * 2011-08-09 2014-08-28 ハイドラ バイオサイエンシズ インコーポレイテッド 一過性受容器電位イオンチャネルtrpa1の阻害
CN103121970B (zh) 2012-12-04 2015-04-29 中国科学院昆明植物研究所 苯并咪唑及其衍生物,其药物组合物及其在制备抗抑郁药物中的应用
PT2970303T (pt) 2013-03-15 2017-06-23 Hydra Biosciences Inc Xantinas substituídas e métodos de sua utilização

Similar Documents

Publication Publication Date Title
JP2016513717A5 (enExample)
JP2016528301A5 (enExample)
JP2016513687A5 (enExample)
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
JP2013519675A5 (enExample)
EA201790525A1 (ru) Применение агента, активирующего рецептор гамк, для получения седативного и анестезирующего лекарственного средства
MX375925B (es) Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
JP2016518337A5 (enExample)
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
MA37455A1 (fr) Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique
IN2013MU03577A (enExample)
EA201890532A1 (ru) Новые аннелированные бензамиды
MA40781A (fr) Composition pharmaceutique d'isotrétinoïne à faible dosage destinée à la voie orale
EA201692298A1 (ru) Производные карбоксамидов
MX387639B (es) Formulaciones farmacéuticas de compuesto de piridinio y un potenciador de la permeabilidad o una base.
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
AR099943A1 (es) Derivados quirales de ácido ciclopentancarboxílico 2,5-disustituidos y su uso
UA117780C2 (uk) Похідні азаіндолоцтової кислоти та їх застосування як модуляторів рецепторів простагландину d2
JOP20190054A1 (ar) مركبات إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
AR058109A1 (es) Acido 3 - (4 - {[4 -(4 -{[3 - (3, 3 - dimetil - 1 - piperidinil)propil]oxi}fenil) - 1 - piperidinil]carbonil} - 1 - naftalenil)propanoico como antagonistas de los receptotres de histamina h1/h3, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamie
TH170295A (th) สารยับยั้ง เตตระไซคลิก โบรโมโดเมน
MX378175B (es) Novedosos compuestos heterocíclicos y su uso tanto en medicina como en cosmética.
TH1701002063A (th) ตัวยับยั้งแอลโดสเทอโรนซินเธส